NEW YORK, Dec. 12, 2016 /PRNewswire/ -- Taxotere lawsuits involving the alleged potential for the chemotherapy agent to cause permanent alopecia (hair loss) continue to move forward in a multidistrict litigation currently underway in the U.S. District Court, Eastern District of Louisiana. According to a Pretrial Order dated November 30th, the Court has established new guidelines pertaining to the filing of requests for summons and summons returns. Summons requests are to be filed in the docket for the member case, as opposed to the master docket. Summons returns and waivers returned executed are not to be filed into any docket, master or member, unless doing so becomes necessary. In such cases (for example, the filing of a motion for default judgment) the summons return is to be filed as an exhibit to the motion, etc., to which it relates. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740
"Our Firm has been contacted by a number of individuals who allegedly experienced permanent hair loss due to the side effects of Taxotere. We will continue to monitor the federal litigation closely for developments that may impact these cases," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others who experienced permanent hair loss following chemotherapy with Taxotere.
Taxotere and Permanent Alopecia
Taxotere (docetaxel) received regulatory approval from the U.S. Food & Drug Administration in 1996 to treat breast cancer, and is now indicated to treat a number of cancers, including head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. However, mention of permanent alopecia as a possible Taxotere side effect wasn't added to the drug's U.S. label until December 2015.
More than 180 Taxotere lawsuits are now pending in the Eastern District of Louisiana. Plaintiffs claim that by the late 1990s, Sanofi-Aventis and other defendants had knowledge of research suggesting more than 9% of patients treated with Taxotere had experienced persistent alopecia for up to 10 years or longer. The lawsuits also cite research published by a Denver-based oncologist in 2006, in which he reported that a higher proportion of his Taxotere patients had suffered from permanent hair loss for years after discontinuing the drug. Finally, plaintiffs assert that Sanofi advised doctors, patients and regulators overseas, including those in the European Union and Canada, that Taxotere is associated with an increased risk of permanent, disfiguring hair loss. Yet, the U.S. labeling merely states that "hair generally grows back" following use of the drug.
Cancer patients who experienced permanent and disfiguring hair loss allegedly related to Taxotere may be entitled to compensation for their emotional distress and other damages. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP